aTyr Pharma, Inc. (ATYR)
Automate Your Wheel Strategy on ATYR
With Tiblio's Option Bot, you can configure your own wheel strategy including ATYR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ATYR
- Rev/Share 0.002
- Book/Share 0.8259
- PB 0.879
- Debt/Equity 0.154
- CurrentRatio 5.9328
- ROIC -0.8512
- MktCap 71128498.0
- FreeCF/Share -1.2558
- PFCF -0.583
- PE -0.9388
- Debt/Assets 0.1159
- DivYield 0
- ROE -1.0011
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ATYR | RBC Capital Mkts | Outperform | Sector Perform | -- | $1.5 | Sept. 16, 2025 |
| Downgrade | ATYR | Leerink Partners | Outperform | Market Perform | -- | $1 | Sept. 15, 2025 |
| Downgrade | ATYR | Cantor Fitzgerald | Overweight | Neutral | -- | -- | Sept. 15, 2025 |
| Downgrade | ATYR | H.C. Wainwright | Buy | Neutral | -- | -- | Sept. 15, 2025 |
| Downgrade | ATYR | Wells Fargo | Overweight | Equal Weight | -- | $1 | Sept. 15, 2025 |
| Initiation | ATYR | Leerink Partners | -- | Outperform | -- | $16 | Feb. 18, 2025 |
| Initiation | ATYR | Cantor Fitzgerald | -- | Overweight | -- | -- | Jan. 6, 2025 |
| Initiation | ATYR | Wells Fargo | -- | Overweight | -- | $17 | Oct. 4, 2024 |
| Initiation | ATYR | Jefferies | -- | Buy | -- | $9 | Sept. 5, 2024 |
News
Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders
Published: December 15, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Dec. 15, 2025 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential derivative claims on behalf of aTyr Pharma, Inc. (NASDAQ: ATYR) concerning alleged fiduciary breaches tied to disclosures around the Phase 3 EFZO-FIT clinical trial. The relevant class action covers November 7, 2024 through September 12, 2025.
Read More
Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders
Published: December 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential derivative claims on behalf of aTyr Pharma, Inc. (NASDAQ: ATYR) concerning alleged fiduciary breaches tied to disclosures around the Phase 3 EFZO-FIT clinical trial.
Read More
Shareholders that lost money on aTyr Pharma, Inc.(ATYR) Urged to Join Class Action – Contact The Gross Law Firm to Learn More
Published: December 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of aTyr Pharma, Inc. (NASDAQ: ATYR).
Read More
ATYR DEADLINE ALERT: Hagens Berman Alerts aTyr Pharma (ATYR) Investors of Today's Lead Plaintiff Deadline in Securities Class Action
Published: December 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Global plaintiffs' rights law firm Hagens Berman reminds investors of the December 8, 2025, deadline to move the Court for appointment as lead plaintiff in the securities class action lawsuit filed against aTyr Pharma, Inc. (NASDAQ: ATYR). The litigation follows a catastrophic 83% single-day stock collapse after the company's flagship drug trial failed to meet its primary endpoint.
Read More
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: December 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Dec. 08, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before December 8, 2025.
Read More
Investors who lost money on aTyr Pharma, Inc.(ATYR) should contact Levi & Korsinsky about pending Class Action - ATYR
Published: December 05, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Dec. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in aTyr Pharma, Inc. ("aTyr" or the "Company") (NASDAQ: ATYR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of aTyr investors who were adversely affected by alleged securities fraud between November 7, 2024 and September 12, 2025.
Read More
aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: December 05, 2025 by: PRNewsWire
Sentiment: Neutral
BENSALEM, Pa. , Dec. 5, 2025 /PRNewswire/ -- The Law Offices of Howard G.
Read More
ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that aTyr Pharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: December 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) and certain of its officers.
Read More
ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure
Published: December 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
Legal Focus on Drug Efficacy: Partner Reed Kathrein Scrutinizing Alleged Misrepresentations of Efzofitimod's Steroid-Tapering Capability Legal Focus on Drug Efficacy: Partner Reed Kathrein Scrutinizing Alleged Misrepresentations of Efzofitimod's Steroid-Tapering Capability
Read More
Deadline Soon: aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
Published: December 04, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming December 8, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) common stock between November 7, 2024 and September 12, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO LOST MONEY ON ATYR PHARMA INC. (ATYR), CLICK HERE TO PARTICIPATE IN THE SEC.
Read More
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
Published: December 04, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in aTyr between January 16, 2025 and September 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Dec. 4, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against aTyr Pharma, Inc. ("aTyr" or the …
Read More
aTyr Pharma, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before December 8, 2025 to Discuss Your Rights - ATYR
Published: December 04, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Dec. 4, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of aTyr Pharma, Inc. (NASDAQ: ATYR). Shareholders who purchased shares of ATYR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
ATYR 5-DAY DEADLINE ALERT: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure
Published: December 03, 2025 by: PRNewsWire
Sentiment: Neutral
Securities Class Action Pending Over Key Drug's Efficacy SAN FRANCISCO , Dec. 3, 2025 /PRNewswire/ -- Global plaintiffs' rights law firm Hagens Berman reminds investors of the December 8, 2025, deadline to move the Court for appointment as lead plaintiff in the securities class action lawsuit filed against aTyr Pharma, Inc. (NASDAQ: ATYR). The litigation follows a catastrophic 83% single-day stock collapse after the company's flagship drug trial failed to meet its primary endpoint.
Read More
ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
Published: December 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options
Read More
aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: December 01, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Dec. 1, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to aTyr Pharma Inc. ("aTyr" or the "Company") (NASDAQ: ATYR) have opportunity to lead the securities fraud class action lawsuit.
Read More
ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that aTyr Pharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: December 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) and certain of its officers.
Read More
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: December 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before December 8, 2025.
Read More
ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure
Published: November 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Legal Focus on Drug Efficacy: Partner Reed Kathrein Scrutinizing Alleged Misrepresentations of Efzofitimod's Steroid-Tapering Capability Legal Focus on Drug Efficacy: Partner Reed Kathrein Scrutinizing Alleged Misrepresentations of Efzofitimod's Steroid-Tapering Capability
Read More
ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that aTyr Pharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: November 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) and certain of its officers.
Read More
ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Announces that aTyr Pharma Investors Have Opportunity to Lead Class Action Lawsuit
Published: November 27, 2025 by: Newsfile Corp
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in aTyr between January 16, 2025 and September 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - November 27, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against aTyr Pharma, Inc. ("aTyr" …
Read More
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: November 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before December 8, 2025.
Read More
aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: November 26, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Nov. 26, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against aTyr Pharma Inc. ("aTyr" or the "Company") (NASDAQ: ATYR). IF YOU SUFFERED A LOSS ON YOUR ATYR INVESTMENTS, CLICK HERE BEFORE DECEMBER 8, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
Read More
aTyr Pharma (ATYR) Securities Class Action Pending Over Key Drug's Efficacy -- Hagens Berman
Published: November 26, 2025 by: PRNewsWire
Sentiment: Neutral
ATYR Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO , Nov. 26, 2025 /PRNewswire/ -- The financial and legal pressures on aTyr Pharma, Inc. (NASDAQ: ATYR) intensified earlier this month as the clinical-stage biotech company reported third-quarter results on Nov. 6 that missed Wall Street estimates, all while navigating high-stakes securities class action litigation. Global plaintiffs' rights firm Hagens Berman has been investigating the alleged claims.
Read More
Portnoy Law Firm Announces Class Action on Behalf of aTyr Pharma, Inc. Investors
Published: November 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 25, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises aTyr Pharma, Inc., (“aTyr” or the "Company") (NASDAQ: ATYR) investors off a class action on behalf of investors that bought securities between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”). aTyr investors have until December 8, 2025 to file a lead plaintiff motion.
Read More
Shareholders that lost money on aTyr Pharma, Inc.(ATYR) Urged to Join Class Action – Contact The Gross Law Firm to Learn More
Published: November 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of aTyr Pharma, Inc. (NASDAQ: ATYR).
Read More
aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug's Efficacy Moves Forward -- Hagens Berman
Published: November 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- The financial and legal pressures on aTyr Pharma, Inc. (NASDAQ: ATYR) intensified earlier this month as the clinical-stage biotech company reported third-quarter results on Nov. 6 that missed Wall Street estimates, all while navigating high-stakes securities class action litigation.
Read More
ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that aTyr Pharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: November 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) and certain of its officers.
Read More
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
Published: November 21, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in aTyr between January 16, 2025 and September 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Nov. 21, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against aTyr Pharma, Inc. ("aTyr" or the …
Read More
aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug's Efficacy Moves Forward -- Hagens Berman
Published: November 20, 2025 by: Newsfile Corp
Sentiment: Neutral
ATYR Investors with Losses Encouraged to Contact Hagens Berman San Francisco, California--(Newsfile Corp. - November 20, 2025) - The financial and legal pressures on aTyr Pharma, Inc. (NASDAQ: ATYR) intensified earlier this month as the clinical-stage biotech company reported third-quarter results on Nov. 6 that missed Wall Street estimates, all while navigating high-stakes securities class action litigation. Global plaintiffs' rights firm Hagens Berman has been investigating the alleged claims.
Read More
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: November 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 20, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before December 8, 2025.
Read More
About aTyr Pharma, Inc. (ATYR)
- IPO Date
- Website https://www.atyrpharma.com
- Industry Biotechnology
- CEO Sanjay S. Shukla
- Employees 56